Molecular Mechanisms of RNA Granule Remodeling in Neurons Under Chronic Cellular Stress

Abstract

Chronic cellular stress in neurons triggers a complex cascade of molecular events, with RNA granule remodeling emerging as a pivotal adaptive and maladaptive process. This review synthesizes current evidence on the molecular mechanisms regulating RNA granule dynamics, particularly stress granules and processing bodies, under sustained stress conditions. We examine the epidemiological context, pathophysiological underpinnings, risk factors, clinical manifestations, diagnostic strategies, and management options. Special emphasis is placed on recent advances in mechanistic understanding and therapeutic potential, offering clinically relevant insights for neurologists and researchers alike.

Introduction

RNA granules, including stress granules (SGs) and processing bodies (PBs), are dynamic ribonucleoprotein assemblies that play crucial roles in mRNA metabolism and neuronal homeostasis. Under physiological conditions, these granules regulate mRNA translation, decay, and storage. However, chronic cellular stress, such as oxidative stress, excitotoxicity, or proteostatic imbalance, can profoundly alter granule dynamics, contributing to neuronal dysfunction and neurodegenerative disease pathogenesis. Understanding the molecular mechanisms of RNA granule remodeling is essential for elucidating disease mechanisms and identifying novel therapeutic targets in neurology.

Epidemiology / Disease Burden

Neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer\"s disease (AD), collectively affect millions worldwide and are characterized by progressive neuronal loss and functional decline. Epidemiological data underscore the rising prevalence of these conditions, attributable in part to increasing life expectancy. Importantly, mounting evidence links aberrant RNA granule remodeling to disease pathogenesis in these disorders, highlighting a significant and growing clinical burden. The interplay between genetic predisposition and environmental stressors amplifies the risk of chronic cellular stress, exacerbating neuronal vulnerability and disease progression.

Pathophysiology

Under chronic cellular stress, neurons activate integrated stress response pathways, leading to phosphorylation of eukaryotic initiation factor 2α (eIF2α) and subsequent inhibition of global protein synthesis. This triggers the assembly of SGs, which transiently sequester translationally stalled mRNAs and associated proteins such as TIA-1, G3BP1, and FUS. PBs, in contrast, are involved in mRNA decay and storage. Prolonged stress impairs granule disassembly, resulting in persistent aggregates that may sequester essential RNA-binding proteins and disrupt normal cellular functions. Emerging data reveal that pathogenic mutations in granule-associated proteins (e.g., TDP-43, FUS, hnRNPA1) enhance granule persistence and promote neurotoxicity. Post-translational modifications, such as phosphorylation, methylation, and ubiquitination, further modulate granule dynamics and contribute to maladaptive responses under chronic stress.

Risk Factors

Genetic mutations affecting RNA-binding proteins (RBPs) or granule-associated proteins represent major risk factors for aberrant granule remodeling. Environmental insults, including chronic oxidative stress, metabolic dysfunction, and neuroinflammation, exacerbate cellular stress responses and promote pathological granule formation. Age-related decline in proteostasis and cellular resilience further heightens vulnerability. Additional risk factors include traumatic brain injury, chronic infections, and exposure to neurotoxins, all of which can potentiate chronic neuronal stress and disrupt RNA granule homeostasis.

Clinical Features

The clinical manifestations associated with disrupted RNA granule dynamics are heterogeneous and largely reflect the underlying neurodegenerative phenotype. Common features include progressive cognitive impairment, motor dysfunction, behavioral changes, and language disturbances. In ALS and FTD, accumulation of granule-associated protein aggregates correlates with neuronal degeneration, muscle weakness, and frontotemporal atrophy. In AD, impaired RNA granule dynamics may contribute to synaptic dysfunction and memory loss. The temporal evolution of symptoms often parallels the accumulation and persistence of aberrant granules in affected brain regions.

Diagnosis

Diagnosis of RNA granule remodeling-related pathology requires a combination of clinical evaluation, neuroimaging, and molecular studies. Advanced neuroimaging modalities, including MRI and PET, can detect region-specific atrophy and metabolic changes. Cerebrospinal fluid (CSF) biomarkers, such as phosphorylated tau, neurofilament light chain, and specific RNA-binding proteins, may aid in early detection. In research settings, immunohistochemistry and fluorescence microscopy allow visualization of SGs and PBs in postmortem brain tissue or cellular models. Next-generation sequencing can identify pathogenic variants in granule-associated genes, facilitating precision diagnostics.

Treatment & Management

Current management strategies for neurodegenerative disorders linked to RNA granule dysregulation are primarily supportive and symptomatic. Pharmacological interventions targeting neurotransmitter systems—such as cholinesterase inhibitors, glutamate antagonists, and dopaminergic agents—provide modest benefit. Non-pharmacological approaches, including cognitive rehabilitation and physical therapy, are integral to maintaining functional independence. Recent preclinical studies suggest that modulators of stress response pathways (e.g., ISR inhibitors, autophagy enhancers) may attenuate pathological granule formation and improve neuronal survival. However, robust clinical trial evidence is still lacking, and no disease-modifying therapies specifically targeting granule remodeling are currently available.

Recent Advances / Emerging Therapies

Recent advances in molecular neurobiology have elucidated key regulators of RNA granule assembly and disassembly, offering novel therapeutic opportunities. Small molecule modulators of eIF2α phosphorylation (e.g., ISRIB), autophagy inducers, and chaperone-based therapies are under investigation for their ability to promote granule clearance and restore neuronal function. Antisense oligonucleotides targeting mutant RBPs or their transcripts have shown promise in preclinical models. High-throughput screening has identified compounds that selectively disrupt aberrant granule interactions without impairing physiological granule functions. These emerging therapies hold potential for disease modification, pending validation in clinical trials.

Guideline Recommendations

While formal clinical guidelines for managing RNA granule remodeling are not yet established, expert consensus emphasizes early recognition of neurodegenerative symptoms, comprehensive risk assessment, and multidisciplinary care. Genetic counseling is recommended for patients with familial forms of disease or identified pathogenic mutations. Participation in clinical trials evaluating novel granule-targeted therapies should be encouraged. Ongoing research and guideline updates are essential as mechanistic insights continue to evolve.

Conclusion

RNA granule remodeling represents a central mechanism linking chronic cellular stress to neuronal dysfunction and degeneration. Advances in understanding the molecular pathways governing granule dynamics have illuminated potential therapeutic targets and underscored the clinical relevance of this process in neurodegenerative diseases. Continued research is critical for translating these insights into effective, mechanism-based interventions that can alter disease trajectories and improve patient outcomes.